3,918 reports of this reaction
1.4% of all CYCLOPHOSPHAMIDE INJECTION, SOLUTION reports
#20 most reported adverse reaction
MYELOSUPPRESSION is the #20 most commonly reported adverse reaction for CYCLOPHOSPHAMIDE INJECTION, SOLUTION, manufactured by Alembic Pharmaceuticals Inc.. There are 3,918 FDA adverse event reports linking CYCLOPHOSPHAMIDE INJECTION, SOLUTION to MYELOSUPPRESSION. This represents approximately 1.4% of all 284,200 adverse event reports for this drug.
Patients taking CYCLOPHOSPHAMIDE INJECTION, SOLUTION who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a less commonly reported adverse event for CYCLOPHOSPHAMIDE INJECTION, SOLUTION, but still significant enough to appear in the safety profile.
In addition to myelosuppression, the following adverse reactions have been reported for CYCLOPHOSPHAMIDE INJECTION, SOLUTION:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 3,918 FDA reports for CYCLOPHOSPHAMIDE INJECTION, SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 1.4% of all adverse event reports for CYCLOPHOSPHAMIDE INJECTION, SOLUTION, making it a notable side effect.
If you experience myelosuppression while taking CYCLOPHOSPHAMIDE INJECTION, SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.